7068 Koll Center Parkway
65 articles with 10X Genomics
Shares of 10X Genomics surged more than 35% on its first day of trading to close at $52.75, well above its $39 initial price offering starting point.
In the lawsuit Bio-Rad asserts that 10X Genomics infringes U.S. Patent No. 8,871,444, which is exclusively licensed to Bio-Rad from Harvard University and the Medical Research Council.
Bio-Rad Laboratories, Inc. announces that the Delaware District Court granted Bio-Rad’s motion for permanent injunction against 10X Genomics from making any sales of infringing products to new customers and granting Bio-Rad’s request for supplemental damages and pre- and post-judgement interest.
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don't stop looking. You never know what may come your way!
The gene sequencing industry has really taken off in the years since the Human Genome Project’s rough draft was announced in June 2000.
Underscores Strong Business and Innovation Momentum
Bay Area-based genomics company 10X Genomics has become one of the fastest growing privately-held companies in the region with an earnings increase of more than 2,000 percent over a three-year period.
Bio-Rad and the University of Chicago Win Patent Infringement Case Against 10X Genomics Related to Droplet Microfluidics Technologies
The jury unanimously found that all Single Cell and Linked-Read genomics products sold by 10X Genomics willfully infringed the patents owned by the University of Chicago and licensed to Bio-Rad.
In what appears to be a trend, big pharma company AbbVie is leasing 479,000 square feet of space inBioMed Realty’s Gateway of Pacific project in South San Francisco.
Introduces significant advances to its flagship Single Cell Gene Expression Solution
The two biggest areas for biotech startups in the U.S. are Cambridge in Boston and the San Francisco Bay Area. They’re also the locations of astonishingly expensive real estate. But they’re where biotechs seem to want to be because they’re close to talent, academic research institutions, and the ...
10X Genomics, a leader in the genomics field, today announced its first acquisition with Epinomics , a pioneer in the growing epigenetics space.
10x Genomics Partners with BioLegend and Immudex to Extend Research Applications of Its New Single Cell Feature Barcoding Technology
The newly developed applications have potential to accelerate disease research and drug discovery in oncology, neurology, infections disease, and immunology in addition to enhancing cell atlas research initiatives.
10x Genomics Extends their Application Portfolio with the Launch of Single Cell Mouse Immune Profiling Solution
New solution characterizes single cell gene expression and paired receptor sequences of T- and B-cells in mouse models of disease
Philibert will focus on cultivating a culture of innovation and excellence for 10x Genomics employees worldwide.
Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
The funding was led by Meritech Capital Partners and included new investor Wells Fargo Strategic Capital along with current investors Paladin Capital, Fidelity and the SoftBank Group.
- Early access researchers will present data at the annual meeting of the American Association for Cancer Research in Chicago this week. -
—CanSeq150 Initiative will use 10x Genomics’ Chromium de novo Assembly Solution to generate high quality, cost-effective assemblies for new genomes—
10X Genomics., a company focused on accelerating genomic discovery, today announced that it has joined the Corporate Partnership Program of the European Molecular Biology Laboratory.